Core Viewpoint - Zimmer Biomet Holdings, Inc. has significantly underperformed the broader market, with stock prices declining sharply over the past year, despite some positive sales growth in its recent quarterly results [2][4]. Company Overview - Zimmer Biomet, based in Warsaw, Indiana, operates as a medical technology company focused on designing, manufacturing, and marketing orthopedic reconstructive products. The company has a market capitalization of $17.6 billion and serves various healthcare professionals and institutions [1]. Stock Performance - ZBH stock has dropped 16.2% year-to-date and 19.2% over the past 52 weeks, contrasting with the S&P 500 Index's returns of 16.4% in 2025 and 14.1% over the past year [2]. - The company has also underperformed compared to the US Medical Devices Ishares ETF, which gained 7.2% in 2025 and 3.5% over the past 52 weeks [3]. Recent Financial Results - Following the release of mixed Q3 results on November 5, ZBH's stock fell 15.2% in a single trading session. The company reported a 5% increase in organic sales on a constant currency basis and a 3.6% rise in overall sales due to acquisition-related growth, with net sales reaching $2 billion, a 9.7% year-over-year increase [4]. - Despite a positive currency translation impact of 1.1%, sales fell short of market expectations by 42 basis points. However, adjusted EPS grew 9.2% year-over-year to $1.90, exceeding consensus estimates by 1.1% [4]. Future Earnings Expectations - For the full fiscal year 2025, analysts project an adjusted EPS of $8.17, reflecting a 2.1% year-over-year increase. The company has a strong earnings surprise history, having surpassed bottom-line estimates in the last four quarters [5]. - Among 27 analysts covering ZBH, the consensus rating is a "Moderate Buy," consisting of seven "Strong Buys," two "Moderate Buys," 16 "Holds," and two "Strong Sells" [5]. Analyst Ratings and Price Targets - Canaccord Genuity analyst Caitlin Roberts maintained a "Hold" rating on ZBH but reduced the price target from $101 to $93. The mean price target of $103.48 indicates a 16.9% premium to current price levels, while the highest target of $135 suggests a potential upside of 52.5% [7].

Core Insights - Evolution Petroleum reported a revenue of $21.29 million for the quarter ended September 2025, reflecting a decrease of 2.8% year-over-year and a surprise of -1.9% compared to the Zacks Consensus Estimate of $21.7 million [1] - The earnings per share (EPS) was reported at $0, down from $0.02 in the same quarter last year, resulting in a -100% surprise against the consensus EPS estimate of $0.02 [1] Financial Performance - The company’s total oil and gas production was 7,315.00 BOE/D, exceeding the two-analyst average estimate of 7,277.00 BOE/D [4] - Average sales prices for key products were as follows: Natural gas at $2.74 (below the estimated $3.03), Natural gas liquids at $23.30 (above the estimated $22.93), and Crude oil at $62.18 (above the estimated $60.14) [4] Market Performance - Over the past month, shares of Evolution Petroleum have returned -7.1%, contrasting with the Zacks S&P 500 composite's +4.4% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Cantaloupe (CTLP) reported revenue of $80.85 million for the quarter ended September 2025, marking a year-over-year increase of 14.1% and an EPS of $0.06 compared to $0.04 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $81.64 million, resulting in a surprise of -0.96%, while the EPS surprise was -25% against a consensus estimate of $0.08 [1] Revenue Breakdown - Transaction fees generated $48.06 million, which was below the estimated $50.79 million, reflecting a year-over-year increase of 10.2% [4] - Equipment sales reached $10.53 million, exceeding the estimated $7.99 million, representing a significant year-over-year increase of 49.5% [4] - Subscription and transaction fees totaled $70.33 million, compared to the average estimate of $73.45 million, with a year-over-year change of 10.2% [4] - Subscription fees amounted to $22.27 million, slightly below the estimated $22.82 million, showing a year-over-year increase of 10.3% [4] Stock Performance - Cantaloupe's shares have returned -0.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of +4.4% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Duke Energy reported $8.54 billion in revenue for Q3 2025, a year-over-year increase of 4.8% and a surprise of +1.48% over the Zacks Consensus Estimate of $8.42 billion [1] - The EPS for the quarter was $1.81, compared to $1.62 a year ago, with a surprise of +4.02% over the consensus estimate of $1.74 [1] Revenue Breakdown - Regulated natural gas operating revenues were $361 million, below the average estimate of $504.2 million, with a year-over-year change of +21.1% [4] - Regulated electric operating revenues reached $8.11 billion, exceeding the $7.5 billion average estimate, reflecting a +4.3% year-over-year change [4] - Nonregulated electric and other revenues were $75 million, below the estimated $82.64 million, showing a -7.4% change compared to the previous year [4] - Gas Utilities and Infrastructure revenues were $394 million, surpassing the average estimate of $357.26 million, with an +18.7% year-over-year change [4] - Electric Utilities and Infrastructure revenues were $8.18 billion, slightly above the estimated $8.12 billion, indicating a +4.2% change year-over-year [4] Stock Performance - Duke Energy's shares returned -0.6% over the past month, compared to the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - Aspen Aerogels reported a revenue of $73.02 million for the quarter ended September 2025, reflecting a year-over-year decline of 37.8% and an EPS of -$0.06 compared to $0.11 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $74.39 million, resulting in a surprise of -1.85% [1] - The company did not deliver an EPS surprise, with the consensus EPS estimate being $0 [1] Financial Performance Metrics - Revenue from the Energy Industrial segment was $24.3 million, below the estimated $26.48 million, representing a year-over-year decline of 9.3% [4] - Revenue from the Thermal Barrier segment was $48.7 million, exceeding the estimated $46.81 million, but showing a significant year-over-year decline of 46.3% [4] - Gross Profit for the Thermal Barrier segment was reported at $11.93 million, lower than the estimated $15.15 million, while Gross Profit for the Energy Industrial segment was $8.87 million, also below the estimated $9.49 million [4] Stock Performance - Aspen Aerogels' shares have returned -10.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of +1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - AvePoint, Inc. reported a revenue of $109.73 million for the quarter ended September 2025, reflecting a year-over-year increase of 23.6% [1] - The earnings per share (EPS) for the quarter was $0.10, up from $0.06 in the same quarter last year, indicating a significant improvement [1] - The reported revenue exceeded the Zacks Consensus Estimate of $105.88 million by 3.64%, while the EPS surpassed the consensus estimate of $0.07 by 42.86% [1] Financial Metrics - Annual recurring revenue (ARR) reached $390 million, slightly above the two-analyst average estimate of $389.75 million [4] - Revenue from services was reported at $13.77 million, exceeding the average estimate of $11.66 million based on two analysts [4] - Revenue from maintenance was $0.84 million, which fell short of the average estimate of $1.35 million based on two analysts [4] Stock Performance - AvePoint's shares have declined by 6.4% over the past month, contrasting with the Zacks S&P 500 composite's increase of 1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - AMN Healthcare Services reported a decline in revenue and earnings for the quarter ended September 2025, with a notable surprise in EPS performance compared to analyst expectations [1][3]. Financial Performance - Revenue for the quarter was $634.5 million, down 7.7% year-over-year, but exceeded the Zacks Consensus Estimate of $615.14 million by 3.15% [1]. - Earnings per share (EPS) was $0.39, a decrease from $0.61 in the same quarter last year, but significantly higher than the consensus estimate of $0.19, resulting in an EPS surprise of 105.26% [1]. Segment Performance - Physician and leadership solutions reported revenue of $178.21 million, slightly above the average estimate of $175.12 million, but down 1.3% year-over-year [4]. - Nurse and allied solutions generated $361.48 million in revenue, surpassing the estimated $346.66 million, but reflecting a 9.5% decline compared to the previous year [4]. - Technology and workforce solutions achieved $94.81 million in revenue, exceeding the average estimate of $93.42 million, with an 11.8% year-over-year decrease [4]. Operating Income - Segment operating income for nurse and allied solutions was $28.76 million, above the estimated $24.57 million [4]. - Operating income for technology and workforce solutions was $30.89 million, below the average estimate of $33.09 million [4]. - Physician and leadership solutions had an operating income of $15.73 million, slightly above the estimated $15.37 million [4]. Stock Performance - AMN Healthcare shares returned 7.1% over the past month, outperforming the Zacks S&P 500 composite, which saw a 1.3% change [3]. - The stock currently holds a Zacks Rank of 5 (Strong Sell), indicating potential underperformance in the near term [3].

Core Insights - Appian (APPN) reported $187 million in revenue for Q3 2025, marking a year-over-year increase of 21.4% and exceeding the Zacks Consensus Estimate by 7.58% [1] - The company's EPS for the quarter was $0.32, significantly higher than the $0.15 reported a year ago, resulting in a surprise of 540% compared to the consensus estimate of $0.05 [1] Financial Performance - Subscriptions gross margin was reported at 87.9%, slightly below the estimated 88.1% [4] - Professional services gross margin stood at 30.9%, surpassing the average estimate of 28% [4] - Revenue from professional services reached $39.82 million, exceeding the estimated $33.67 million and reflecting a year-over-year increase of 28.7% [4] - Subscription revenue was $147.19 million, above the average estimate of $140.16 million, representing a year-over-year growth of 19.6% [4] Market Performance - Over the past month, Appian's shares have returned -0.7%, while the Zacks S&P 500 composite increased by 1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Viewpoint - Alcon is expected to report quarterly earnings of $0.77 per share, a decline of 4.9% year-over-year, with revenues projected at $2.59 billion, reflecting a 6.5% increase compared to the previous year [1] Earnings Projections - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Total Surgical' to be $1.42 billion, a 6.1% increase from the prior-year quarter [4] - 'Net Sales- Total Vision Care' is expected to reach $1.17 billion, suggesting a 7.1% year-over-year change [4] Detailed Sales Estimates - 'Net Sales- Total Surgical- Consumables' is estimated at $743.89 million, reflecting a 6.1% increase from the previous year [5] - 'Net Sales- Total Surgical- Equipment/other' is projected at $245.51 million, indicating a 14.2% year-over-year increase [5] - 'Net Sales- Total Vision Care- Contact lenses' is expected to be $724.58 million, a 9.1% increase year-over-year [6] - 'Net Sales- Total Vision Care- Ocular health' is forecasted at $448.60 million, showing a 4.1% change from the prior-year quarter [6] Regional Sales Forecast - 'Net Sales- Total Surgical- Implantables' is projected to reach $430.00 million, a 1.9% increase from the previous year [7] - 'Revenues- Other revenues' are expected to be $19.52 million, indicating a 7.1% decline year-over-year [7] - 'Net sales by region- United States' is forecasted at $1.16 billion, reflecting a 4.6% year-over-year increase [7] - 'Net sales by region- International' is expected to reach $1.43 billion, suggesting an 8.2% increase from the prior-year quarter [8] Stock Performance - Alcon shares have decreased by 2.9% in the past month, contrasting with the Zacks S&P 500 composite's increase of 1.3% [8] - With a Zacks Rank 2 (Buy), Alcon is anticipated to outperform the overall market performance in the near term [8]

Core Viewpoint - Wall Street analysts predict that DuPont de Nemours (DD) will report a quarterly earnings of $1.04 per share, reflecting an 11.9% year-over-year decline, with revenues expected to be $2.63 billion, a decrease of 17.7% compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 15.1% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price performance [3]. Key Metrics Projections - Analysts estimate 'Net Sales- IndustrialsCo' to reach $2.10 billion, indicating a year-over-year increase of 51.7% [5]. - 'Net Sales- ElectronicsCo' is forecasted to be $1.22 billion, reflecting a decline of 21.6% from the previous year [5]. - 'Operating EBITDA- ElectronicsCo' is expected to be $394.86 million, down from $467.00 million in the same quarter last year [5]. - 'Operating EBITDA- Corporate & Other' is projected at -$34.00 million, compared to $26.00 million reported in the same quarter last year [6]. - 'Operating EBITDA- IndustrialsCo' is anticipated to reach $515.11 million, up from $364.00 million a year ago [6]. Stock Performance - DuPont de Nemours shares have experienced a return of -52.1% over the past month, contrasting with the Zacks S&P 500 composite's +1% change, indicating expected underperformance in the near future [6].